soul trial oral semaglutide (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine Oral Semaglutide Cuts Cardiovascular Risk

Level-1 is so delicious that you'll wonder how you ever got by using anything else

Retrieved 13 November 2022

BCL-2 and glutathione: alterations in cellular redox state that regulate apoptosis sensitivity

These two peptides are also being researched in the contexts of injuries to the brain, stroke, ALS, and Alzheimers disease, among other conditions

However hard I pretend to be a body positive feminist, I was raised in the Noughties, idolising Nicole Ritchie and the Olsen twins

Important Information When exploring GLP-1 medication, it is advisable to consult with a qualified healthcare provider who has experience in obesity management and is well-versed in the use of this medication